Creatine supplementation in Parkinson disease: A placebo-controlled randomized pilot trial
Andreas Bender(Hertie Institute for Clinical Brain Research), Walter Koch(Hertie Institute for Clinical Brain Research), Matthias Elstner(University of Tübingen), Y. Schombacher(University of Tübingen), Julia Glade Bender(Hertie Institute for Clinical Brain Research), M. Moeschl(Hertie Institute for Clinical Brain Research), Florian Gekeler(Hertie Institute for Clinical Brain Research), Bertram Müller‐Myhsok(Hertie Institute for Clinical Brain Research), Thomas Gasser(University of Tübingen), Klaus Tatsch(University of Tübingen), Thomas Klopstock(Hertie Institute for Clinical Brain Research)
Cited by 203
Abstract
Mitochondrial dysfunction plays a major role in the pathogenesis of Parkinson disease (PD). Creatine (Cr) is an ergogenic compound that exerts neuroprotective effects in animal models of PD. We conducted a 2-year placebo-controlled randomized clinical trial on the effect of Cr in 60 patients with PD. Cr improved patient mood and led to a smaller dose increase of dopaminergic therapy but had no effect on overall Unified Parkinson9s Disease Rating Scale scores or dopamine transporter SPECT.
Related Papers
No related papers found
Powered by citation graph analysis